36P PROUDER-BC: PROsigna in UnDer-50-year-old patients (pts) with endocrine receptor-positive (ER+) breast cancer (BC) for chemotherapy (CT) prescription
Francesco Schettini(Target (United States)), Gabriela Cobos(Tufts Medical Center), G Grazia(Breast Cancer Research Foundation), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Grazia Arpino(University of Naples Federico II), A. Caltavituro(Federico II University Hospital), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), A. Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Michela Palleschi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Vincenzo Di Lauro(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Benjamín Walbaum, O. Cano Cano(Corporació Sanitària Parc Taulí), Darío Sánchez(Hospital Universitario La Paz), T. Pascual(Hospital Clínic de Barcelona), D. Morchón Araujo(Universidad de Salamanca), A. López Paradís, C.A.A. Rodríguez Sánchez(Universidad de Salamanca)
Cited by 0
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282